Ambrobene oral solution 7.5 mg/ml, 100ml — Made in Germany — Free Delivery

A small number of cases of severe skin reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome)) have been reported associated with the use of expectorants such as ambroxol hydrochloride. basically they could be explained by the severity of the underlying disease and / or the simultaneous use of another preparation. therefore, if new lesions of the skin or mucous membranes appear, you should immediately seek medical attention and stop treatment with ambroxol hydrochloride.

During the early stages of Stevens-Johnson syndrome or Lyell's syndrome, the patient may develop non-specific, flu-like symptoms such as fever, body aches, rhinitis, cough, and sore throat. Mistakenly, with such nonspecific, like signs of the onset of influenza symptoms, symptomatic treatment with preparations for cough and cold is used.

Since ambroxol can increase mucus secretion, Ambrobene syrup should be used with caution in case of impaired bronchial motility and increased mucus secretion (for example, in such a rare disease as primary ciliary dyskinesia).

In patients with severe renal failure, the accumulation of hepatic metabolites of ambroxol is possible. In patients with impaired renal function and severe liver disease, Ambroxol should be used only after consulting a doctor. In this case, it is recommended to reduce the dose and increase the time between doses of the preparation.

Caution is needed in patients with gastric or duodenal ulcers.

In patients with asthma and severe asthmatic attacks, ambroxol syrup should be used with caution.

Ambrobene syrup contains sorbitol. 5 ml of syrup contains 2.1 g of sorbitol (which corresponds to 0.18 XE) and is a source of 0.53 g of fructose. Patients with rare hereditary forms of fructose intolerance should not take this preparation.

Ambrobene syrup contains sodium saccharin, which should be taken into account in patients with diabetes mellitus.

Patients with rare hereditary forms and intolerance to galactose, Lapp lactase deficiency or malabsorption of glucose and galactose should not take the preparation in tablet form.

The ability to influence the reaction rate when driving or working with other mechanisms. There is no data on the effect on the reaction rate when driving or operating other mechanisms. Studies of the effect on the reaction rate when driving vehicles or working with other mechanisms have not been carried out.

Use during pregnancy and lactation. Pregnancy. There is insufficient data on the use of ambroxol in pregnant women, especially for the period up to the 28th week of pregnancy. Ambroxol has not shown any teratogenic effects in animal studies.

However, you should follow the usual precautions when taking medications during pregnancy. Especially in the first trimester of pregnancy, it is not recommended to use this preparation.

Lactation. Ambroxol hydrochloride passes into breast milk. Although not expected to have adverse effects on infants, Ambroxol is not recommended for use during breastfeeding.

Children. Syrup and solution are used in children aged 2 years and older.

The preparation in the form of prolonged-release capsules should not be used in children. For children, it is recommended to use the preparation in the form of a syrup and solution. Tablets are used in children aged 6 years and older who do not tolerate syrup or solution for inhalation and ingestion.

In children under 6 years of age, apply Ambrobene in the form of syrup and drops.

Ambrobene is not recommended to be taken simultaneously with preparations with antitussive activity (for example, codeine), as this will lead to difficulty in removing sputum from the bronchi against the background of a decrease in the severity of cough.